guest ::
| Home > Publications database > MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. > print |
| Home > Publications database > MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. > print |
| 001 | 127516 | ||
| 005 | 20240228140933.0 | ||
| 024 | 7 | _ | |a 10.1016/j.molonc.2015.01.008 |2 doi |
| 024 | 7 | _ | |a pmid:25732226 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC5528752 |2 pmc |
| 024 | 7 | _ | |a 1574-7891 |2 ISSN |
| 024 | 7 | _ | |a 1878-0261 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2017-03539 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Shukla, Kirti |0 P:(DE-HGF)0 |b 0 |e First author |
| 245 | _ | _ | |a MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2015 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1521640183_922 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Nuclear Factor kappa B (NF-κB) signaling is frequently deregulated in a variety of cancers and is constitutively active in estrogen receptor negative (ER-) breast cancer subtypes. These molecular subtypes of breast cancer are associated with poor overall survival. We focused on mechanisms of NF-κB regulation by microRNAs (miRNAs), which regulate eukaryotic gene expression at the post-transcriptional level. In a previous genome-wide miRNA screen, we had identified miR-30c-2-3p as one of the strongest negative regulators of NF-κB signaling. Here we have uncovered the underlying molecular mechanisms and its consequences in breast cancer. In vitro results show that miR-30c-2-3p directly targets both TNFRSF1A-associated via death domain (TRADD), an adaptor protein of the TNFR/NF-κB signaling pathway, and the cell cycle protein Cyclin E1 (CCNE1). Ectopic expression of miR-30c-2-3p downregulated essential cytokines IL8, IL6, CXCL1, and reduced cell proliferation as well as invasion in MDA-MB-231 breast cancer cells. RNA interference (RNAi) induced silencing of TRADD phenocopied the effects on invasion and cytokine expression caused by miR-30c-2-3p, while inhibition of CCNE1 phenocopied the effects on cell proliferation. We further confirmed the tumor suppressive role of this miRNA using a dataset of 781 breast tumors, where higher expression was associated with better survival in breast cancer patients. In summary we have elucidated the mechanism by which miR-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression in breast cancer. |
| 536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a CCNE1 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Cyclin E |2 NLM Chemicals |
| 650 | _ | 7 | |a MIRN30 microRNA, human |2 NLM Chemicals |
| 650 | _ | 7 | |a MicroRNAs |2 NLM Chemicals |
| 650 | _ | 7 | |a NF-kappa B |2 NLM Chemicals |
| 650 | _ | 7 | |a Oncogene Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a RNA, Neoplasm |2 NLM Chemicals |
| 650 | _ | 7 | |a TNF Receptor-Associated Death Domain Protein |2 NLM Chemicals |
| 700 | 1 | _ | |a Sharma, Ashwini Kumar |0 P:(DE-He78)ef6b064b6d3463cee768ed2e261c10cd |b 1 |u dkfz |
| 700 | 1 | _ | |a Ward, Aoife |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Will, Rainer |0 P:(DE-He78)18218139eec55d83cf82679934e5cd75 |b 3 |u dkfz |
| 700 | 1 | _ | |a Hielscher, Thomas |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 4 |u dkfz |
| 700 | 1 | _ | |a Balwierz, Aleksandra |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Breunig, Christian |0 P:(DE-He78)cfaf278e8f522c72644cee2a753d2845 |b 6 |u dkfz |
| 700 | 1 | _ | |a Münstermann, Ewald |0 P:(DE-He78)610dc3a15bda751de4d4c52373b2620f |b 7 |u dkfz |
| 700 | 1 | _ | |a König, Rainer |0 P:(DE-He78)4291b9a1fa95bfd7a810372e2d629c32 |b 8 |u dkfz |
| 700 | 1 | _ | |a Keklikoglou, Ioanna |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Wiemann, Stefan |0 P:(DE-He78)f6bebe05e7a748d3cbf9f59659567d52 |b 10 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.molonc.2015.01.008 |g Vol. 9, no. 6, p. 1106 - 1119 |0 PERI:(DE-600)2322586-5 |n 6 |p 1106 - 1119 |t Molecular oncology |v 9 |y 2015 |x 1574-7891 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:127516 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)ef6b064b6d3463cee768ed2e261c10cd |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)18218139eec55d83cf82679934e5cd75 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)cfaf278e8f522c72644cee2a753d2845 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)610dc3a15bda751de4d4c52373b2620f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)4291b9a1fa95bfd7a810372e2d629c32 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)f6bebe05e7a748d3cbf9f59659567d52 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |2 G:(DE-HGF)POF3-300 |v Functional and structural genomics |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL ONCOL : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOL ONCOL : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)B050-20160331 |k B050 |l Molekulare Genomanalyse |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B080-20160331 |k B080 |l Theoretische Bioinformatik |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)W110-20160331 |k W110 |l Microarray Unit |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B050-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B080-20160331 |
| 980 | _ | _ | |a I:(DE-He78)W110-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|